CEO Jesse Shefferman was paid $2,655,774 in fiscal year 2025, ↑ up 48.2% from fiscal year 2024 (SEC filing 0001213900-26-048536 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,655,774 ↑ Jesse Shefferman total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | 94.63% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
TARA's next annual pay disclosure, estimated May 1, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jesse Shefferman | $654,888 | $0 | $294,450 | $1,277,216 | $351,184 | $0 | $78,036 | $2,655,774 |
| President, Chief Executive Officer and Director | ||||||||
| Leonardo Nicacio | 373,864 | 75,000 | 208,500 | 453,435 | 229,753 | 0 | 41,931 | 1,382,483 |
| Chief Medical Officer | ||||||||
| Jacqueline Zummo | 494,000 | 0 | 110,985 | 481,844 | 219,521 | 0 | 75,924 | 1,382,274 |
| Chief R&D Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jesse Shefferman | $2,655,774 | $1,791,843 | — | ↑ +863,931 |
| Leonardo Nicacio | 1,382,483 | — | — | — |
| Jacqueline Zummo | 1,382,274 | 1,214,189 | — | ↑ +168,085 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Protara Therapeutics's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper TARA reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses TARA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TARA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Jacqueline Zummo | Chief R&D Officer | $1,382,274 |
| Jesse Shefferman | CEO | $2,655,774 |
| Leonardo Nicacio | Chief Medical Officer | $1,382,483 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Barry Flannelly, Pharm.D | Independent Director | $100,991 |
| Cynthia Smith | Independent Director | $106,991 |
| Gregory Sargen | Independent Director | $109,991 |
| Jane Huang, M.D | Independent Director | $119,991 |
| Luke Beshar | Chair of the Board | $226,491 |
| Michael Solomon, Ph.D | Independent Director | $107,491 |
| Richard Levy, M.D | Independent Director | $149,491 |
| Roger Garceau, M.D | Independent Director | $121,491 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jacqueline Zummo | RSU | 6,633 | — | $35,354 |
| Jacqueline Zummo | Option | 71,355 | 1.91 | — |
| Jesse Shefferman | RSU | 17,099 | — | 91,138 |
| Jacqueline Zummo | Option | 32,311 | 3.02 | — |
| Jesse Shefferman | Option | 5,282 | 6.9 | — |
| Jesse Shefferman | Option | 185,938 | 1.91 | — |
| Jacqueline Zummo | RSU | 24,500 | — | 130,585 |
| Jacqueline Zummo | Option | 146,000 | 4.53 | — |
| Jesse Shefferman | RSU | 65,000 | — | 346,450 |
| Leonardo Nicacio | RSU | 50,000 | — | 266,500 |
| Jesse Shefferman | RSU | 39,332 | — | 209,640 |
| Jacqueline Zummo | RSU | 15,333 | — | 81,725 |
| Jesse Shefferman | Option | 83,282 | 3.02 | — |
| Jacqueline Zummo | Option | 1,767 | 6.9 | — |
| Jesse Shefferman | Option | 387,000 | 4.53 | — |
| Leonardo Nicacio | Option | 150,000 | 4.17 | — |
Compensation of named executive officers is designed to enable the company to attract, retain, and motivate talented and experienced executives, with a focus on pay-for-performance principles and alignment with stockholders' interests.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Consulting, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-12 | 29,208,205 | 1,656,994 | 48,666 | 94.63% | Passed |
| 2025 | 2025-06-11 | 20,420,306 | 134,110 | 2,055,728 | 99.35% | Passed |
| 2024 | 2024-06-07 | 6,999,091 | 196,457 | 2,585,674 | 97.27% | Passed |
| 2023 | 2023-06-07 | 5,571,777 | 296,338 | 62,576 | 94.95% | Passed |
| 2022 | 2022-06-08 | 6,426,881 | 126,276 | 54,902 | 98.07% | Passed |
| 2021 | 2021-06-09 | 6,310,191 | 97,531 | 18,597 | 98.48% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-12 | 94.63%a |
| 2025 | 2025-06-11 | 99.35%b |
| 2024 | 2024-06-07 | 97.27%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Luke BesharIndependent · Board Chair · Audit · Nominating and Corporate Governance (Chair) | $171,500 | $0 | $54,991 | — | $0 | $226,491 |
| Richard Levy, M.DIndependent | 94,500 | 0 | 54,991 | — | 0 | 149,491 |
| Roger Garceau, M.DIndependent | 66,500 | 0 | 54,991 | — | 0 | 121,491 |
| Jane Huang, M.DIndependent | 65,000 | 0 | 54,991 | — | 0 | 119,991 |
| Gregory SargenIndependent · Audit (Chair) | 55,000 | 0 | 54,991 | — | 0 | 109,991 |
| Michael Solomon, Ph.DIndependent | 52,500 | 0 | 54,991 | — | 0 | 107,491 |
| Cynthia SmithIndependent · Compensation (Chair) | 52,000 | 0 | 54,991 | — | 0 | 106,991 |
| Barry Flannelly, Pharm.DIndependent | 46,000 | 0 | 54,991 | — | 0 | 100,991 |
| Jesse SheffermanEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $603,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $603,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Protara Therapeutics | 2025 | Jesse Shefferman | $654,888 | $294,450 | $1,277,216 | $351,184 | $2,655,774 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Jesse Shefferman | DEF 14A | 2026-04-28 | 0001213900-26-048536 | Section “Executive Compensation”. As printed: 2,655,774. Filing ↗machine: r1 · c16 · span 701928–701937 |
| 2 | Section 01, Leonardo Nicacio | DEF 14A | 2026-04-28 | 0001213900-26-048536 | Section “Executive Compensation”. As printed: 1,382,483. Filing ↗machine: r3 · c16 · span 721275–721284 |
| 3 | Section 01, Jacqueline Zummo | DEF 14A | 2026-04-28 | 0001213900-26-048536 | Section “Executive Compensation”. As printed: 1,382,274. Filing ↗machine: r5 · c16 · span 737490–737499 |
| 4 | Section 08, Luke Beshar | DEF 14A | 2026-04-28 | 0001213900-26-048536 | Section “Director Compensation”. As printed: 226,491. Filing ↗machine: span 1239748–1240127 |
| 5 | Section 08, Richard Levy, M.D | DEF 14A | 2026-04-28 | 0001213900-26-048536 | Section “Director Compensation”. As printed: 149,491. Filing ↗machine: span 1255506–1255885 |
| 6 | Section 08, Roger Garceau, M.D | DEF 14A | 2026-04-28 | 0001213900-26-048536 | Section “Director Compensation”. As printed: 121,491. Filing ↗machine: span 1247632–1248011 |
| 7 | Section 08, Jane Huang, M.D | DEF 14A | 2026-04-28 | 0001213900-26-048536 | Section “Director Compensation”. As printed: 119,991. Filing ↗machine: span 1251558–1251937 |
| 8 | Section 08, Gregory Sargen | DEF 14A | 2026-04-28 | 0001213900-26-048536 | Section “Director Compensation”. As printed: 109,991. Filing ↗machine: span 1259430–1259809 |
| 9 | Section 08, Michael Solomon, Ph.D | DEF 14A | 2026-04-28 | 0001213900-26-048536 | Section “Director Compensation”. As printed: 107,491. Filing ↗machine: span 1267305–1267684 |
| 10 | Section 08, Cynthia Smith | DEF 14A | 2026-04-28 | 0001213900-26-048536 | Section “Director Compensation”. As printed: 106,991. Filing ↗machine: span 1263373–1263752 |
| 11 | Section 08, Barry Flannelly, Pharm.D | DEF 14A | 2026-04-28 | 0001213900-26-048536 | Section “Director Compensation”. As printed: 100,991. Filing ↗machine: span 1243683–1244062 |
| 12 | Section 08, Jesse Shefferman | DEF 14A | 2026-04-28 | 0001213900-26-048536 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 06, 2026 vote | Form 8-K | 2026-06-15 | 0001213900-26-068774 | Item 5.07 · say-on-pay result. As reported: 94.63% (votes for as printed: 29,208,205). Filing ↗ |
| 14 | Section 06, 2025 vote | Form 8-K | 2025-06-12 | 0001213900-25-053844 | Item 5.07 · say-on-pay result. As reported: 99.35% (votes for as printed: 20,420,306). Filing ↗ |
| 15 | Section 06, 2024 vote | Form 8-K | 2024-06-10 | 0001213900-24-051210 | Item 5.07 · say-on-pay result. As reported: 97.27% (votes for as printed: 6,999,091). Filing ↗ |
| 16 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 17 | Section 09b board cost (computed) | Computed | — | — | Cash 603,000 + equity 0 + all other 0 = 603,000, summed across the director compensation table rows.machine: formula: Σ = 603,000 |
| 18 | Protara Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0001213900-26-048536 | CEO total compensation as printed in Protara Therapeutics's own proxy. As printed: 2,655,774. Filing ↗machine: r1 · c16 · span 701928–701937 |